We studied Medline (Ovid) from August 4th to August 31st 2020 on a weekly basis for our fourth monthly update of our living review using our previous methods and this gave us 82 results and after a double review, 24 fresh studies were discovered that met our eligibility including 19 observational studies, 4 meta-analyses, and 1 systematic review.
19 observational studies can be relied upon with previous proofs discovered an absence of involvement of angiotensin-converting enzyme inhibitor (ACEI) with angiotensin-receptor blocker (ARB) use and more severe coronavirus disease 2019 (COVID-19). Before developing COVID-19, usage of ACEIs or ARBs may improve results as suggested by some studies.
Two meta-analyses addressed our first key question about the use of ACEIs and ARBs and COVID-19 risk, discovering that ACEI or ARB usage is not associated with the risks of COVID-19 disease.
Hence this combination of the 24 studies of this updated sears did not change the surety of the proof rating that was reported in the actual script for the first and second questions. The advantages and disadvantages of initiating ACEIs and ARBs in COVID-19 treatment have not been examined, thus the proof for the third question still remains uncertain.